Satio is thrilled to share news of securing a contract from the Biomedical Advanced Research and Development Authority (BARDA), a division of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services. This contract aims to develop an innovative, disposable, and swift diagnostic tool for detecting ebolavirus.

This pioneering diagnostic solution will merge Satio's patch-based blood collection technology with Institut Pasteur de Dakar's advanced and rapid immunoassay for ebolavirus. This integrated device will empower community health workers to effortlessly administer a rapid and precise test in remote areas, enabling the swift identification and treatment of infected individuals.

By moving away from the traditional fingerstick blood samples and the associated handling of blood samples elsewhere, Satio's innovation not only reduces exposure to bloodborne pathogens but also establishes an affordable and distinctive diagnostic approach that can be effortlessly deployed where needed. This advancement is pivotal in enhancing patient outcomes and curtailing the transmission of the ebolavirus.

Satio is actively working on a series of patch-based platforms, including SatioDot™ for dried blood spots and SatioDraw™ for collecting whole blood, which facilitate various laboratory-based tests. These platforms employ a lancet to draw blood from the upper arm onto the patch. With the funding from BARDA's Division of Research, Innovation, and Ventures (DRIVe), Satio is expediting the creation of an integrated system for blood collection and diagnostics. This platform's capabilities can later be expanded to identify other critical bloodborne pathogens, such as HIV and syphilis.

In a bid to ensure that this platform remains affordable and accessible to Low- and Middle-Income Countries (LMICs), Satio is collaborating with Sapphiros to manufacture the diagnostic tool utilizing Sapphiros' ingenious and exclusive high-volume manufacturing process.

Namal Nawana, the Executive Chairman and Founder of Satio, commented, "Satio's range of patch-based solutions for blood collection, diagnostics, and drug delivery is designed to revolutionize healthcare workflows. This partnership, involving BARDA DRIVe, Institut Pasteur de Dakar, Sapphiros, and Satio, empowers us to create cost-effective, high-performance diagnostics that can be rapidly deployed in response to biosecurity threats, such as ebolavirus."

 

Source: prnewswire.com

Report Abuse